A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach

Br J Haematol. 2018 Jul;182(1):125-128. doi: 10.1111/bjh.14726. Epub 2017 May 3.

Authors

Michal Haran¹, Vita Mirkin¹, Andrei Braester², Nurith Harpaz¹, Olga Shevetz¹, Marina Shtreiter¹, Shulamit Greenberg¹, Orly Mordich¹, Orna Amram¹, Inbal Binsky-Ehrenreich³, Ayelet Marom³, Idit Shachar³, Yair Herishanu⁴, Rosa Ruchlemer⁵, Alain Berrebi¹, Liora Valinsky¹, Mordechai Shtalrid¹, Lev Shvidel¹

Affiliations

¹ Haematology Institute, Kaplan Medical Centre, affiliated with the Hebrew University, Rehovot, Israel.
² Haematology Institute, Galilee Medical Centre, Nahariya, Israel.
³ Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
⁴ Department of Haematology, Sourasky Medical Centre and Sackler Faculty of Medicine, Tel-Aviv ‏University, Tel Aviv, Israel.
⁵ Department of Haematology, Shaare Zedek, Jerusalem, Israel.

PMID: 28466956
DOI: 10.1111/bjh.14726

No abstract available

Keywords: Phase I clinical trial; chronic lymphocytic leukaemia; elderly patients; milatuzumab; performance status.

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Antigens, Differentiation, B-Lymphocyte / immunology
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Female
Frail Elderly
Histocompatibility Antigens Class II / immunology
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Patient-Centered Care / methods
Quality of Life

Substances

Antibodies, Monoclonal, Humanized
Antigens, Differentiation, B-Lymphocyte
Antineoplastic Agents, Immunological
Histocompatibility Antigens Class II
invariant chain
milatuzumab